Centessa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	6.85	0	0	0	0
Gross Profit	6.85	0	0	0	0
Selling, General & Admin	53.73	55.2	42.89	1.14	0.79
Research & Development	124.41	155.08	95.66	9.3	4.26
Other Operating Expenses	5.43	-0.36	239.91	0	0
Operating Expenses	183.56	209.92	378.45	10.44	5.05
Operating Income	-176.71	-209.92	-378.45	-10.44	-5.05
Interest Expense / Income	9.91	7.28	1.17	0.07	-0.01
Other Expense / Income	-10.48	-0.24	1.33	0.16	-10.11
Pretax Income	-176.14	-216.95	-380.96	-10.66	5.06
Income Tax	-25.06	-0.75	0.11	0	0
Net Income	-151.09	-216.21	-381.07	-10.66	5.06
Shares Outstanding (Basic)	96	93	75	86	-
Shares Outstanding (Diluted)	96	93	75	-	-
Shares Change	2.97%	24.26%	-12.52%	-	-
EPS (Basic)	-1.57	-2.31	-5.07	-	-
EPS (Diluted)	-1.57	-2.31	-5.07	-	-
Free Cash Flow	-160.51	-201.68	-135.3	-10.63	-5.83
Free Cash Flow Per Share	-1.67	-2.16	-1.80	-0.12	-
Gross Margin	100.00%	-	-	-	-
Operating Margin	-2578.59%	-	-	-	-
Profit Margin	-2204.65%	-	-	-	-
Free Cash Flow Margin	-2342.20%	-	-	-	-
EBITDA	-165.43	-209.55	-379.75	-10.6	5.06
EBITDA Margin	-2413.91%	-	-	-	-
Depreciation & Amortization	0.81	0.13	0.03	0	0.01
EBIT	-166.24	-209.68	-379.79	-10.6	5.06
EBIT Margin	-2425.73%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).